Abbott Laboratories (ABT) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pac...
Abbott Laboratories's revenue increased 5.7% year over year, from $41.95B to $44.33B.
Net income decreased 51.3% over the same period, from $13.40B to $6.52B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 113% in total.
Total debt decreased by 21.6% to $9.90B.
The debt-to-equity ratio stands at 0.19, indicating a conservative leverage profile.
Operating cash flow grew 11.8% to $9.57B.
Abbott Laboratories maintains a healthy net profit margin of 14.7%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $10.63B+2.5% | $1.65B | $5.94B | $1.86B | $2.71B | $74.36B | $12.82B | $39.80B |
| Q4 FY2024 | $10.97B+3.2% | $9.23B | $6.03B | $1.91B | $2.87B | $81.41B | $12.63B | $47.66B |
| Q1 FY2025 | $10.36B-5.6% | $1.32B | $5.89B | $1.69B | $1.42B | $81.45B | $12.74B | $48.81B |
| Q2 FY2025 | $11.14B+7.6% | $1.78B | $6.29B | $2.05B | $2.05B | $84.00B | $12.93B | $50.56B |
| Q3 FY2025 | $11.37B+2.0% | $1.64B | $6.29B | $2.06B | $2.79B | $84.18B | $11.60B | $50.95B |
| Q4 FY2025 | $11.46B+0.8% | $1.78B | $6.54B | $2.25B | $3.31B | $86.71B | $9.90B | $52.13B |
| Q1 FY2026 | $11.16B-2.6% | $1.08B | $6.27B | $1.34B | $1.31B | $110.43B | $34.14B | $52.70B |
| Q2 FY2026 | $12.59B+12.8% | $928.0M | $7.27B | $1.69B | $2.49B | $109.22B | $32.72B | $51.76B |
Balance Sheet Summary (Q2 FY2026)
Abbott Laboratories (ABT) Financial Statements & Revenue History
Abbott Laboratories (ABT) is a US-listed stock operating in the Healthcare sector, specifically the Medical Devices industry trading at $104.13 with a market capitalization of $180. This page provides 42 historical financial statements for Abbott Laboratories, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Abbott Laboratories reported revenue of $44.3 billion, representing 5.7% year-over-year growth. The net profit margin of 14.7% indicates moderate profitability. The debt-to-equity ratio of 0.19 shows conservative leverage.
ABT Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Abbott Laboratories's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether ABT is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track ABT's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Abbott Laboratories converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of ABT's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use ABT Financial Data
Investors use Abbott Laboratories's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare ABT's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how ABT's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View ABT's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Abbott Laboratories's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.ABT trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.